

Keywords: advanced gastric cancer; S-1 plus cisplatin therapy; TSU-68

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

W Koizumi^{*1}, K Yamaguchi², H Hosaka³, Y Takinishi⁴, N Nakayama⁵, T Hara⁶, K Muro⁷, H Baba⁸, Y Sasaki⁹, T Nishina¹⁰, N Fuse¹¹, T Esaki¹², M Takagi¹³, M Gotoh¹⁴ and T Sasaki¹⁵

¹Department of Gastroenterology, Kitasato University East Hospital, Sagami-hara 228-8520, Japan; ²Department of Gastroenterology, Saitama Cancer Center, Ina-machi 362-0806, Japan; ³Division of Gastroenterology, Gunma Prefectural Cancer Center, Ota 373-8550, Japan; ⁴Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama 224-8503, Japan; ⁵Department of Gastroenterology, Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization, Yokohama 241-8515, Japan; ⁶Department of Surgery, Kouseiren Takaoka Hospital, Takaoka 933-8555, Japan; ⁷Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan; ⁸Department of Gastroenterological Surgery, Kumamoto University Hospital, Kumamoto 860-8556, Japan; ⁹Department of Medical Oncology, Saitama Medical University International Medical Center, Hidaka 350-1241, Japan; ¹⁰Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan; ¹¹Division of Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan; ¹²Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan; ¹³Department of Surgery, Shizuoka General Hospital, Shizuoka 420-8527, Japan; ¹⁴Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki 569-8686, Japan and ¹⁵Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 113-8677, Japan

Background: This study aimed to determine whether combination S-1 plus cisplatin (CDDP) therapy, the most widely used therapy for Japanese patients with advanced gastric cancer, and the novel oral antiangiogenic agent TSU-68 could contribute to gastric cancer treatment.

Methods: Ninety-three patients with chemotherapy-naïve unresectable or recurrent advanced gastric cancers were randomised into two groups: TSU-68 plus S-1/CDDP (group A) and S-1/CDDP (group B) groups. Both patient groups received identical S-1 and CDDP dosages. TSU-68 was orally administered for 35 consecutive days. Group B patients received S-1 orally twice daily for three consecutive weeks, followed by intravenous CDDP on day 8. The primary endpoint was progression-free survival (PFS).

Results: Median PFS periods were 208 and 213 days in groups A and B, respectively ($P=0.427$). Median survival periods for groups A and B were 497.0 and 463.5 days, respectively ($P=0.219$). No statistically significant differences were noted for PFS, survival or the adverse event (AE) incidence rate. All AEs were expected according to previous reports for TSU-68, TS-1, and CDDP.

Conclusion: Combination therapy involving TSU-68, S-1, and CDDP was safe and well tolerated in patients with chemotherapy-naïve unresectable or recurrent advanced gastric cancers. However, factors related to therapeutic efficacy should be investigated further.

Gastric cancer is the second most common cause of cancer death both worldwide (Jemal *et al*, 2011) and in Japan (Sobue *et al*, 2012).

Since Macdonald *et al* (1980) reported the use of 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C combination chemotherapy (median survival time, 5.5 months) for the treatment of

*Correspondence: Dr W Koizumi; E-mail: koizumi@med.kitasato-u.ac.jp
This study is registered with JAPIC Clinical Trial Information (JapicCTI- 101327).

Received 31 May 2013; revised 30 July 2013; accepted 19 August 2013;
published online 17 September 2013

© 2013 Cancer Research UK. All rights reserved 0007–0920/13



unresectable, advanced, or recurrent gastric cancers in 1980, multidrug chemotherapies, particularly those that include 5-FU, have been the most widely used therapies worldwide. Currently, the employed regimens differ among geographic regions. For example, epirubicin, cisplatin (CDDP), and 5-FU; epirubicin, oxaliplatin, and capecitabine (EOX); and docetaxel, CDDP, and 5-FU chemotherapies are primarily used in the control arms of clinical studies in Western countries, whereas 5-FU and CDDP chemotherapy is primarily used in non-Western countries. Thus, no global consensus has been reached on a standard therapy.

In Japan, the clinical development of chemotherapies for unresectable, advanced, or recurrent gastric cancers has progressed for many years, and many clinical studies have been conducted using TS-1 (S-1), a fluoropyrimidine anticancer drug that is produced in Japan. When compared with continuous intravenous 5-FU infusion, 5-FU/CDDP did not significantly increase life expectancy (Ohtsu *et al.*, 2003); since then, 5-FU alone has been used as a reference arm. Nevertheless, the American Society of Clinical Oncology reported the results from two Japanese phase III clinical studies (Japan Clinical Oncology Group (JCOG) 9912 (Boku *et al.*, 2009) and S-1 Plus cisplatin vs S-1 in RCT in the Treatment for Stomach cancer (SPIRITS) (Koizumi *et al.*, 2008)) in 2007. Japan Clinical Oncology Group 9912 demonstrated that S-1 capsule monotherapy was not inferior to continuous intravenous 5-FU infusion in terms of overall survival (OS). In addition, the SPIRITS trial reported a significantly prolonged OS with S-1/CDDP therapy and a better (prolonged by >1 year) OS than that with S-1 alone. Therefore, a first-line standard chemotherapy was established in Japan.

The median survival period achieved in the SPIRITS trial was 13.0 months; therefore, further improvements to the therapeutic results are necessary. In recent years, the use of a fluoropyrimidine anticancer drug in combination with molecular targeted agents has been studied, and vascular endothelial growth factor (VEGF) is assumed to be closely related to tumour proliferation in gastric cancers (Laird *et al.*, 2000). The use of bevacizumab, a monoclonal antibody that targets VEGF A, was evaluated in combination with capecitabine and cisplatin as a first-line therapy for advanced gastric cancer (Ohtsu *et al.*, 2011). In that study, the progression-free survival (PFS) and overall response rates (ORRs) were significantly improved with bevacizumab; however, no survival benefit related to this drug was noted. On the other hand, ramucirumab, a monoclonal antibody that targets VEGF receptor 2, significantly prolonged OS when used as a second-line monotherapy for advanced gastric or gastroesophageal junction adenocarcinoma (Fuchs *et al.*, 2013).

TSU-68 (orantinib) is a novel oral antiangiogenic agent that has been shown to inhibit the tyrosine phosphorylation of VEGF receptor 2, platelet-derived growth factor (PDGF) receptor 6, and fibroblast growth factor (FGF) receptor 1 *in vitro* (Kim *et al.*, 2009). Previously, phase I and phase II studies in patients with breast cancer, hepatocellular carcinoma (HCC), lung cancer, and colorectal cancer were conducted in Asia (Kanai *et al.*, 2010; Okamoto *et al.*, 2012; Shin *et al.*, 2012; Toi *et al.*, 2012; Inaba *et al.*, 2013), and a phase III study was initiated in 2010 to evaluate the survival benefit of TSU-68 in patients with intermediate-stage HCC (ClinicalTrials.gov Identifier: NCT01465464). As part of the clinical development of TSU-68, a combination of S-1/CDDP therapy, the most widely used therapy in Japan for patients with advanced gastric cancers, and TSU-68, which has antiangiogenic effects, was expected to be an effective gastric cancer treatment. Consequently, we conducted a phase II randomised study to compare the effects of a combination therapy with 3 agents—TSU-68, S-1, and CDDP—with the effects of S-1/CDDP therapy with regard to the PFS to improve the therapeutic results of first-line standard chemotherapies.

MATERIALS AND METHODS

Patients. The patients included in the study were ≥ 20 years with (1) histologically or cytologically confirmed adenocarcinoma, (2) unresectable or recurrent gastric cancer, and (3) no prior systemic treatment. Recurrent patients were eligible if the last dose of postoperative adjuvant chemotherapy had been received at least 180 days before the start of the study. Other eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0–1 and adequate functioning of the major organs, along with the following laboratory values: haemoglobin, ≥ 8.0 g dl⁻¹, neutrophil count, ≥ 1500 mm⁻³, platelet count, $\geq 100\,000$ mm⁻³, serum creatinine, \leq the reference value at the study center, and serum bilirubin (TBIL), ≤ 1.5 mg dl⁻¹. Other laboratory criteria included a creatinine clearance of ≥ 60 ml min⁻¹, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of ≤ 100 U l⁻¹, and an alkaline phosphatase (ALP) level that was 2.5-fold less than the reference value at the study center. For patients with liver metastases, those with AST, ALT, and ALP values that were 5-fold less than the reference values at the study center were eligible. In addition, patients were required to have target tumours that were measurable by computed tomography, magnetic resonance imaging, or radiography in accordance with the Response Evaluation Criteria in Solid Tumours (RECIST), ver. 1.0. All patients were required to provide written consent. This study was implemented in accordance with Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki.

Design. This was a phase II, multicenter, randomised, controlled study to estimate the efficacy of TSU-68 plus S-1/CDDP therapy vs S-1/CDDP therapy. Randomisation was performed according to the minimisation method, using ‘unresectable gastric cancer’, ‘recurrent gastric cancer with postoperative adjuvant chemotherapy’, and ‘recurrent gastric cancer without postoperative adjuvant chemotherapy’ as the stratification factors. Eligible patients were randomly assigned to either the TSU-68 plus S-1/CDDP (group A) or the S-1/CDDP (group B) groups at a ratio of 1:1 (Figure 1).

In groups A and B, S-1 was administered at a dose of < 40 mg m⁻². The S-1 dose was calculated according to the patient’s body surface area as follows: < 1.25 m², 40 mg; 1.25–1.5 m², 50 mg; and > 1.5 m², 60 mg. S-1 was orally administered twice daily for three consecutive weeks. CDDP was administered at a dose of 60 mg m⁻² by intravenous infusion on day 8. The duration of each cycle was 5 weeks (35 days). In group A, 400 mg of TSU-68 was orally administered twice daily (total daily dosage, 800 mg) for five consecutive weeks. The treatments were continued until 1 of the following occurred: progressive disease (PD), unacceptable toxicity, withdrawal of patient consent (regardless of toxicity), or termination of treatment at the discretion of the attending physician.




Figure 1. Study design. Two patients were excluded from the full analysis set by an independent data monitoring committee.

The protocol was approved by the Institutional Review Board of each study center. The Independent Data Review Committee evaluated safety throughout the study period. This study was conducted in compliance with the Declaration of Helsinki and the Japanese GCP Guidelines.

Endpoints and evaluation methods. The primary endpoint was PFS, which was defined as the period from the day of enrolment to the day on which (1) radiological or clinical progression was evident, (2) subsequent treatment was indicated, or (3) the patient died. The earliest day among these defined days was considered. If patients were lost to follow-up because of second-line treatment or a transfer to another hospital, their data were censored. Tumours were measured every 5 weeks until the onset of PD. All measured images were assessed by a Central Imaging Review Committee in accordance with the RECIST (New Guideline 2000; Therasse *et al*, 2000).

Secondary endpoints were the antitumour effect (ORR), OS, safety, pharmacokinetics (PK), and the relationship between angiogenesis-related factors and efficacy. To determine safety, blood tests, biochemical analyses, and urinalyses were performed and subjective as well as objective findings were followed-up throughout the study period. Adverse events (AEs) were graded in accordance with the National Cancer Institute Common Toxicity Criteria ver. 3.0.

In the patients who were included in the PK evaluation on day 8, the PK of TSU-68 after repeated administration of TSU-68 (400 mg per dose) on day 8, the PK of tegafur (FT), 5-FU, 5-chloro-2,4-dihydropyridine (CDHP), and potassium oxonate (Oxo) after the repeated administration of S-1 (50–60 mg per dose), and the PK of the total and free platinum levels after the administration of CDDP (60 mg m⁻²) were investigated.

Angiogenesis-related factors were tested at baseline levels and before the start of the next cycle. The following angiogenesis-related factors were measured: PDGF-AA, PDGF-BB, soluble vascular cell adhesion molecule-1, soluble endothelial-leukocyte adhesion molecule-1 in the serum and plasma, and interleukin-8 with enzyme-linked immunosorbent assays (ELISAs; BioSource Europe, Nivelles, Belgium); plasma tissue plasminogen activator (t-PA) with a soluble t-PA ELISA kit (Oncogene Science, Cambridge, MA, USA); and plasma plasminogen activator inhibitor-1, acidic FGF, VEGF, VEGF soluble receptor type 2, hepatocyte growth factor, VEGF-C, VEGF soluble receptor type 3, and the lactate dehydrogenase isozyme.

Statistical analyses. The SPIRITS trial that was conducted in Japan showed that the median PFS achieved with S-1/CDDP was 6 months. According to this result, the PFS with TSU-68 + S-1/CDDP was estimated to be 9 months. This would have a

significant clinical impact on systemic therapy for advanced gastric cancer. We assumed that a total of 86 patients (two groups) would be necessary to demonstrate the superiority of TSU-68 + S-1/CDDP at a power of 80% and a one-sided significance level of 20% with unstratified log-rank tests at the end of the follow-up period (Rubenstein *et al*, 2005). After considering possibilities such as ineligible patients, we determined that 92 patients were required for the study.

We used a full analysis set (FAS), defined as patients who met the eligibility criteria, for the primary analyses of efficacy and safety.

To compare the PK parameters of S-1 and CDDP between groups A and B, the Wilcoxon test was performed for the maximum drug concentration time (t_{max}), and the Student's *t*-test or Aspin-Welch test was performed for parameters other than the t_{max} after logarithmic transformation.

RESULTS

Patient background. Between December 2008 and February 2012, a total of 93 patients (group A, $n = 46$; group B, $n = 47$) from a total of 14 centres in Japan were enrolled and randomised in this study (Figure 2). One patient from group A was found to be ineligible, and 1 patient from group B did not receive treatment. Therefore, a total of 91 patients (group A, $n = 45$ and group B, $n = 46$) were included in the FAS that was used for efficacy and safety analyses. There were no significant imbalances in the patient background characteristics at enrolment between the two groups (Table 1). The percentages of patients with 1, 2, or ≥ 3 organs with infiltration and/or metastasis were 46.7%, 40%, and 13.3%, respectively, in group A and 41.3%, 50%, and 8.7%, respectively, in group B. None of the patients had locally advanced disease alone. Peritoneal metastases were noted in 15 (33.3%) group A patients and 15 (32.6%) group B patients. Histologically, diffuse-type and intestinal-type adenocarcinomas were noted in 23 (48.9%) and 22 (51.1%) group A patients, respectively, and in 20 (54.3%) and 25 (43.5%) group B patients, respectively. Gastrectomies had been performed in 6 (19.6%) group A patients and in 9 (13.3%) group B patients before enrolment. Postoperative adjuvant chemotherapy was administered to 4 (10.9%) group A patients and 5 (8.9%) group B patients.

Efficacy

Progression-free survival. The median PFS were not significantly different between the two groups (group A, 208.0 days; group B, 213 days; $P = 0.424$; Figure 3).




Figure 2. CONSORT diagram. A total of 93 patients (group A, $n = 46$; group B, $n = 47$) were randomised. One patient from group A did not receive treatment, and 1 patient from group B was ineligible. Therefore, a total of 91 patients (group A, $n = 45$; group B, $n = 46$) were included in the FAS used for the efficacy and safety analyses.

Table 1. Patient characteristics

Characteristics	No. of patients		P-value
	Group A	Group B	
Full analysis set	45	46	
Gender			0.360
Male	30	35	
Female	15	11	
Age, years			0.239
65 ≤	26	26	
65 >	19	20	
Median (range)	62.0 (30–74)	63.5 (44–76)	
ECOG PS			0.771
0	28	30	
1	17	16	
2	0	0	
Diagnosis			1.000
Unresectable	39	39	
Recurrent	6	7	
Adjuvant chemotherapy			1.000
–	41	41	
+	4	5	
Histology			0.601
Intestinal	22	25	
Diffuse	23	20	
Unknown	0	1	
No. of organs involved			0.847
1	21	19	
2	18	23	
> 3	6	4	
Metastasis of peritoneum			1.000
–	30	31	
+	15	15	
Metastasis of liver			0.403
–	26	22	
+	19	24	

Abbreviation: ECOG PS = Eastern Cooperative Oncology Group performance status.

The hazard ratio (HR) was 1.23 (95% confidence interval (CI): 0.74–2.05).

Survival. All follow-up investigations were completed at the time of data cutoff in April 2012, which was 1 year and 8 months after the last patient enrolment. Outcomes were confirmed in all patients (100%). Of the 91 patients in the FAS, 33 of the 45 (73.3%) group A patients and 38 of the 46 (82.6%) group B patients died. The median OS periods were 497.0 days in group A and 463.5 days in group B. The 1-year survival rates were 66.7% in group A and 63.0% in group B. The 2-year survival rate was 30.4% in group A and 22.4% in group B. The survival rates in group A were not significantly different from those in group B ($P = 0.213$) (Figure 3). The HR was 0.74 (95% CI: 0.46–1.19).

Best overall response. Twenty-eight of the 45 group A patients achieved a partial response (PR), and thus the response rate was 62.2% (95% CI: 46.5–76.2%). Twenty-six of the 46 group B patients achieved a PR, and thus the response rate was 56.5% (95% CI: 41.1–71.1%). The response rate in group A was not significantly different from that in group B ($P = 0.671$).




Figure 3. Kaplan–Meier analysis of PFS and OS. Of the 93 total patients, 46 were placed into group A and 47 were placed into group B. The median PFS times of the patients in group A and group B were 208.0 days (95% CI: 141.0–274.0 days) and 213.0 days (95% CI: 178.0–309.0 days), respectively. The HR for radiological progression or death in group A was 1.23 (95% CI: 0.74–2.05). The median OS times of the patients in group A and group B were 497.0 days (95% CI: 371.0–635.0 days) and 463.5 days (95% CI: 359.0–554.0 days), respectively. The HR for death in group A was 0.74 (95% CI: 0.46–1.19).

Safety. The AEs that occurred in this study are shown in Table 2. The main AEs that occurred at least 10% more frequently in group A than in group B were as follows: changes in the ALT, AST, and ALP levels, vomiting, diarrhoea, pigmentation abdominal pain, oedema, and urine colour change. The main AEs that occurred at least 10% less frequently in group A than in group B were as follows: neutropenia, changes in the leukocyte, TBIL, and creatinine levels, and stomatitis. The incidence rates of Grade 3 or higher AEs were the same in both groups; however, anorexia and changes in the haemoglobin and platelet levels occurred more frequently in group A than in group B. Specific changes observed in group A and group B patients were as follows: haemoglobin, 48.9% and 26.1%, respectively; platelet, 24.4% and 6.5%, respectively; anorexia, 17.8% and 8.5%, respectively.

In addition, no treatment-related deaths were noted in either group. Only 1 of the 46 patients (2.2%) in group B died within 90 days after enrolment, while only 2 (4.4%) died of aspiration and hypoxia during the study period.

Treatment continuity. The mean actual dose intensity of each drug in groups A and B was as follows: S-1, 80.3% and 83.0%, respectively; CDDP, 89.6% and 92.0%, respectively; and TSU-68, 72.9% in group A. The median relative dose intensity (RDI) for S-1

Table 2. Incidence of adverse events

	Group A (n = 45)						Group B (n = 46)						P-value	
	Grade (n)				Total (%)	Grade 3 < (%)	Grade (n)				Total (%)	Grade 3 < (%)		Any grade
	1	2	3	4			1	2	3	4				
Haemoglobin	7	8	21	1	82.2	48.9	6	17	12	0	76.1	26.1	0.607	
Neutropenia	3	9	13	1	57.8	31.1	4	13	13	3	71.7	34.8	0.192	
Platelets	16	7	6	5	75.6	24.4	25	5	2	1	71.7	6.5	0.813	
Lymphocytes	8	7	8	0	51.1	17.8	4	12	6	0	47.8	13.0	0.835	
Leukocytes	8	12	5	0	55.6	11.1	12	15	5	1	71.7	13.0	0.130	
AST	14	6	2	0	48.9	4.4	15	1	0	0	34.8	0.0	0.205	
ALT	13	3	2	0	40.0	4.4	10	2	0	0	26.1	0.0	0.185	
ALP	14	5	0	1	44.4	2.2	10	0	0	0	21.7	0.0	0.027	
T-Bilirubin	9	3	1	0	28.9	2.2	14	6	1	0	45.7	2.1	0.130	
Albumin	12	12	3	0	60.0	6.7	16	13	0	0	63.0	0.0	0.831	
Creatinine	10	1	0	0	24.4	0.0	16	2	0	1	41.3	2.1	0.119	
Stomatitis	11	1	0	0	26.7	0.0	15	1	1	0	37.0	2.1	0.370	
Anorexia	20	12	7	1	88.9	17.8	18	17	4	0	84.8	8.5	0.758	
Nausea	23	12	0	0	77.8	0.0	21	15	1	0	80.4	2.1	0.801	
Vomiting	17	8	0	0	55.6	0.0	10	9	0	0	41.3	0.0	0.211	
Diarrhoea	16	7	5	0	62.2	11.1	15	7	2	0	52.2	4.3	0.399	
Fatigue	19	14	2	1	80.0	6.7	27	8	3	0	82.6	6.4	0.793	
Pigmentation	28	3	—	—	68.9	—	24	0	—	—	52.2	—	0.134	
Abdominal pain	13	7	1	0	46.7	2.2	7	6	1	0	30.4	2.1	0.134	
Oedema: All	19	7	0	0	57.7	0.0	11	1	0	0	26.1	0.0	0.003	
Urine colour change	44	0	—	—	97.8	—	3	0	—	—	6.5	—	<0.001	

Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase. Adverse events were defined by the National Cancer Institute Common Terminology Criteria (version 3.0). Adverse events were compared with the use of Fisher’s exact test. All reported P-values are two-sided.

was 85.6% in group A and 88.7% in group B. The median RDI for CDDP was 92.5% in group A and 92.9% in group B. Reasons for treatment discontinuation in groups A and B were as follows: PD, 69.6% and 78.7%, respectively; AEs (mainly bone marrow depression), 15.2% and 6.4%, respectively; withdrawal of consent, 4.3% and 4.3%, respectively; and indications for surgery, 10.9% and 4.3%, respectively. A total of 97.8% and 91.2% of patients in groups A and B, respectively, received second-line chemotherapy. At the end of the study, CPT-11-containing regimens were given to 37.8% and 42.9% of the patients in groups A and B, respectively, and taxane-containing regimens were given to 26.7% and 28.9% of the patients in groups A and B, respectively.

Subgroup analyses. Subgroup analyses of the patient backgrounds revealed no prolongation of PFS in any of the subgroups (Figure 4). In addition, neither the baseline nor the post-treatment measurements of the angiogenesis-related factors correlated with efficacy (data not shown).

Pharmacokinetics. The pharmacokinetic parameters of TSU-68, S-1, and CDDP are shown in Table 3.

The mean maximum drug concentration (C_{max}) and the area under the curve of the plasma concentration vs time from 0 to the final time point (AUC_{0-last}) for TSU-68 were $4.46 \mu g ml^{-1}$ and $23.23 \mu g h^{-1} ml^{-1}$, respectively. These values were not significantly different from the previously reported results for TSU-68 monotherapies and combination therapies (Kanai *et al*, 2010;

Murakami *et al*, 2011; Ueda *et al*, 2011; Okamoto *et al*, 2012; Toi *et al*, 2012).

For S-1, the C_{max} and AUC_{0-last} of the FT were significantly lower in group A than in group B, and the half-life ($t_{1/2}$) was significantly shorter in group A than in group B. However, no significant difference was noted between the two groups with regard to the C_{max} or the AUC_{0-last} of 5-FU. The AUC_{0-last} of CDHP and Oxo were significantly lower in group A than in group B.

For CDDP, the C_{max} and the AUC_{0-last} of free platinum were significantly lower in group A than in group B.

DISCUSSION

The median PFS was 208.0 days (95% CI: 141.0–274.0 days) in group A and 213.0 days (95% CI: 178.0–309.0 days) in group B.

According to the Central Imaging Review Committee, none of the patients in either group achieved a complete response. A total of 28 patients in group A and 26 patients in group B achieved a PR. The response rate was 62.2% (95% CI: 46.5–76.2%) in group A and 56.5% (95% CI: 41.1–71.1%) in group B. No additional TSU-68 effect was demonstrated.

The median survival period was 497.0 days (95% CI: 371.0–635.0 days) in group A and 463.5 days (95% CI: 359.0–554.0 days) in group B. Beyond the median point, differences in the survival




Figure 4. Forest plot for PFS. No prolongation of PFS was observed in any of the subgroups.

Table 3. Pharmacokinetic (PK) parameters

	PK parameters					
	Group	No. of patients	t _{max} (h)	C _{max} (µg ml ⁻¹)	AUC _{0-last} (µg h ⁻¹ ml ⁻¹)	t _{1/2} (h)
TSU-68	A	6	3.5 ± 1.5	4.46 ± 0.95	23.2 ± 7.0	2.2 ± 0.7
S-1						
FT	A	12	2.3 ± 0.8	2168 ± 378**	13 368 ± 2581**	6.9 ± 1.1**
	B	12	2.4 ± 1.2	3693 ± 1309	29 219 ± 10 288	13.3 ± 4.4
5-FU	A	12	3.1 ± 0.7	202 ± 65	891 ± 315	1.6 ± 0.3**
	B	12	3.8 ± 1.2	160 ± 37	976 ± 221	2.4 ± 0.6
CDHP	A	12	2.6 ± 0.8	228 ± 55	993 ± 229**	2.9 ± 0.6*
	B	12	2.7 ± 1.1	263 ± 94	1442 ± 337	3.8 ± 0.8
Oxo	A	12	3.3 ± 1.8	44 ± 22*	258 ± 133*	3.2 ± 0.9
	B	12	3.0 ± 1.7	90 ± 59	498 ± 285	4.6 ± 2.3
CDDP						
Free platinum	A	6	1.7 ± 0.5	1277 ± 169*	2813 ± 360*	0.783 ± 0.071
	B	7	2.0 ± 0.0	1585 ± 284	3441 ± 437	0.819 ± 0.070

Abbreviations: CDHP = 5-chloro-2,4-dihydropyridine; FT = 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4-(1H,3H)-dione (tegafur); 5-FU = 5-fluorouracil; Oxo = monopotassium 1,2,3,4-tetrahydro-2,4-dioxo-1,3,5-triazine-6-carboxylate (oxonic acid). Mean ± s.d. *P-value <0.05; **P-value <0.001.

curve indicated that a small number of patients in group A tended to have prolonged survival; however, per the stratified analyses, no correlation with efficacy was observed.

No statistically significant differences were noted for any of the endpoints, which included PFS, response rate, and survival.

With regard to the safety profile, no significant difference was observed in the AE incident rates between the groups, except for changes in ALP levels, oedema, and urine colour change (Table 2). Although the incidence of changes in the ALP levels tended to be higher in group A than in group B (44.4% and 21.7%, respectively), most of these patients with ALP level alterations had Grade 1 or Grade 2 AEs. Oedema and urine colour change are typical AEs of TSU-68, and almost of them were not severe and controlled enough. All AEs were expected according to previous reports on AEs for TSU-68, TS-1, and CDDP. The addition of TSU-68 to TS-1 plus CDDP, a standard therapy, is unlikely to induce serious or fatal events.

On the other hand, although the evaluation of the quality of life (QOL) was recently determined to be important in the evaluation of tolerability, we did not collect data on the QOL in the present study.

From the results of the TSU-68 PK profile in group A, S-1 and CDDP are unlikely to influence the PK of TSU-68. The induction of FT metabolism by TSU-68 could be a reason for the decreased AUC of FT in group A, as CYP1A2 has been reported to have a minor role in the metabolism of FT to 5-FU (Komatsu *et al*, 2000), and TSU-68 has the potential to induce CYP1A2 (Kitamura *et al*, 2008). The effects of TSU-68 on plasma exposure to CDHP and Oxo cannot be denied; however, TSU-68 had no effect on plasma exposure to 5-FU, the active ingredient of S-1. Therefore, combination therapy with TSU-68 was unlikely to affect the efficacy or safety of S-1. In the CDDP PK analysis, the plasma exposure to free platinum significantly decreased when TSU-68 was administered in combination with S-1/CDDP, but the degree of this decrease was not remarkable (~20%). The effect of this slight decrease in platinum exposure on the efficacy and safety of CDDP is unknown. Therefore, further studies are required to investigate the interaction between TSU-68 and CDDP.

Molecular target therapies are increasingly being developed for the treatment of gastric cancer. Trastuzumab was found to induce a substantial increase in OS in HER-2-positive patients with metastatic gastric cancer when combined with chemotherapy (Bang *et al*, 2010). The antiangiogenic agent bevacizumab, in combination with capecitabine and cisplatin as a first-line therapy, significantly improved the PFS rate and ORR; however, no survival benefit related to this drug was noted (Ohtsu *et al*, 2011). Ramucirumab significantly prolonged OS when used as a second-line monotherapy (Fuchs *et al*, 2013). An understanding of past studies of molecular target agents is necessary for appropriate patient selection.

Taken together, our results show that a combination therapy that comprised TSU-68, TS-1, and CDDP was safe and well tolerated in patients with unresectable or recurrent gastric cancers. However, TSU-68 did not demonstrate the expected enhanced efficacy. Further studies to explore all aspects that affect efficacy are necessary.

ACKNOWLEDGEMENTS

We are grateful to Dr Junji Tanaka and Dr Atsushi Sato, who served as the Central Imaging Review Committee. We are also grateful to Yutaka Ariyoshi, Tomohide Tamura, and Yuh Sakata who served as an Independent Data Review Committee. This trial was supported by Taiho Pharmaceutical Co., Ltd.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* **376**: 687–697.
- Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A. Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. *Lancet Oncol* **10**: 1063–1069.
- Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Tabernero J, Zalberg JR, Chau I, Koshiji M, Hsu Y, Schwartz JD, Ajani JA (2013) REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. *J Clin Oncol* **31**(4_suppl): LBA5.
- Inaba F, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, Kudo M, Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y (2013) A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolization. *Eur J Cancer* **49**: 2832–2840
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. *CA Cancer J Clin* **61**: 69–90.
- Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, Kondo Y, Taniguchi M, Tagawa K, Ikeda M, Morizane C, Okusaka T, Arioka H, Shiina S, Omata M (2010) A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. *Cancer Chemother Pharmacol* **67**: 315–324.
- Kim SE, Shim KN, Jung SA, Yoo K, Lee JH (2009) The clinicopathological significance of tissue levels of hypoxia-inducible factor-1 α and vascular endothelial growth factor in gastric cancer. *Gut Liver* **3**: 88–94.
- Kitamura R, Asanoma H, Nagayama S, Otagiri M (2008) Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68). *Drug Metab Dispos* **36**: 1003–1009.
- Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol* **9**: 215–221.
- Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T (2000) Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. *Drug Metab Dispos* **28**: 1457–1463.
- Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. *Cancer Res* **60**: 4152–4160.
- Macdonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C (1980) 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. *Ann Intern Med* **93**: 533–536.
- Murakami H, Ueda Y, Shimoyama T, Yamamoto N, Yamada Y, Arioka H, Tamura T (2011) Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor,

- administered after meals with solid tumors. *Cancer Chemother Pharmacol* **67**: 1119–1128.
- Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol* **29**: 3968–3976.
- Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S. Japan Clinical Oncology Group Study (JCOG9205) (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* **21**: 54–59.
- Okamoto I, Yoshioka H, Takeda K, Satouchi M, Yamamoto N, Seto T, Kasahara K, Miyazaki M, Kitamura R, Ohyama A, Hokoda N, Nakayama H, Yoshihara E, Nakagawa K (2012) Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. *J Thorac Oncol* **7**: 427–433.
- Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA (2005) Design issues of randomized phase II trials and a proposal for phase II screening trials. *J Clin Oncol* **23**: 7199–7206.
- Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB (2012) A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. *Invest New Drugs* **30**: 1501–1510.
- Sobue T, Katanoda K, Ajiki W, Tsukuma H, Ioka A (2012) Gan Tokei Hakusho 2012. pp 1–14. Shinoharashinsha Publishers: Tokyo, Japan.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* **92**: 205–216.
- Toi M, Saeki T, Iwata H, Inoue K, Tokuda Y, Sato Y, Ito Y, Aogi K, Takatsuka Y, Arioka H (2012) A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. *Breast Cancer*; e-pub ahead of print 2 March 2012; doi:10.1007/s12282-012-0344-3.
- Ueda Y, Shimoyama T, Murakami H, Yamamoto N, Yamada Y, Arioka H, Tamura T (2011) Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. *Cancer Chemother Pharmacol* **67**: 1101–1109.



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>